What one share of Senti Biosciences Holdings holds
We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches.
Senti Biosciences Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.71 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.32 |
| Cash and investments | $0.21 |
| Book value | −$0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$189.95 | $19.03 | −$137.96 | — | −$374.97 |
| 2022 | — | −$22.29 | $15.85 | −$29.21 | — | $28.88 |
| 2023 | — | −$16.01 | $2.71 | −$14.52 | — | $14.64 |
| 2024 | — | −$12.04 | $0.01 | −$9.01 | — | $5.31 |
| 2025 | $0.00 | −$2.73 | $0.01 | −$1.94 | — | $0.18 |
Common questions about Senti Biosciences Holdings
How much does one share of Senti Biosciences Holdings earn?
Over the last 12 months, Senti Biosciences Holdings lost $1.71 for each share on $0.00 of sales.
Does Senti Biosciences Holdings pay a dividend?
Senti Biosciences Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Senti Biosciences Holdings’s book value per share?
Senti Biosciences Holdings’s book value is negative (−$0.11 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Senti Biosciences Holdings have?
Each share of Senti Biosciences Holdings has $0.21 of cash and investments, as of June 30, 2026.
What is Senti Biosciences Holdings’s free cash flow per share?
−$1.32 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Senti Biosciences Holdings bought back shares?
Senti Biosciences Holdings’s share count rose about 7620% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.